



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of : Customer Number: 20277
Dmitry CHERKASOV, et al. : Confirmation Number: 5625
Application No.: 10/578,313 : Group Art Unit: 3661
Filed: July 18, 2007 : Examiner: Not Yet Assigned
For: MACROMOLECULAR NUCLEOTIDE COMPOUNDS AND METHODS FOR USING
THE SAME

RESPONSE TO NOTIFICATION OF DEFECTIVE RESPONSE

Box PCT
Commissioner for Patents
Washington, DC 20231

Sir:


In response to the Notification of Defective Response dated July 17, 2008, submitted herewith are the following documents for filing in the above-referenced application:

1. English language translation of application.

Please charge any shortage in fees due in connection with the filing of this paper, including extension of time fees, to Deposit Account 500417 and please credit any excess fees to such deposit account.

Respectfully submitted,

McDERMOTT WILL & EMERY LLP


Judith L. Toffenetti
Registration No. 39,048

600 13th Street, N.W.
Washington, DC 20005-3096
Phone: 202.756.8000 JLT:alb
Facsimile: 202.756.8087
Date: July 24, 2008

**Please recognize our Customer No. 20277
as our correspondence address.**




UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
10/578,313	Dmitry Cherkasov	076030-0011

20277
MCDERMOTT WILL & EMERY LLP
600 13TH STREET, N.W.
WASHINGTON, DC 20005-3096



McDermott Will & Emery LLP
DC Office

INTERNATIONAL APPLICATION NO.	
PCT/EP04/12556	
I.A. FILING DATE	PRIORITY DATE
11/05/2004	11/05/2003

CONFIRMATION NO. 5625
371 FORMALITIES LETTER



Date Mailed: 07/17/2008

NOTIFICATION OF DEFECTIVE RESPONSE

The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as a Designated Office (37 CFR 1.494):

- Priority Document
- Copy of the International Application filed on 01/17/2007
- English Translation of the IA filed on 07/18/2007
- Copy of IPE Report filed on 05/04/2006
- Preliminary Amendments filed on 07/18/2007
- Biochemical Sequence Diskette filed on 01/17/2007
- Oath or Declaration filed on 05/04/2006
- Biochemical Sequence Listing filed on 01/17/2007
- Small Entity Statement filed on 01/17/2007
- Request for Immediate Examination filed on 05/04/2006
- U.S. Basic National Fees filed on 05/04/2006
- Priority Documents filed on 05/04/2006
- Power of Attorney filed on 05/04/2006
- Specification filed on 07/18/2007
- Claims filed on 07/18/2007
- Abstracts filed on 07/18/2007
- Drawings filed on 07/18/2007

Applicant's response filed 01/17/2007 is hereby acknowledged. The following requirements set forth in the NOTIFICATION of MISSING REQUIREMENTS mailed 01/18/2007 have not been completed.

The following items **MUST** be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371:

- Translation of the application into English. Note a processing fee will be required if submitted later than 30 months from the priority date.

SUMMARY OF FEES DUE:

Total additional fees required for this application is \$-2760 for a Large Entity:

Applicant is required to complete the response within a time limit of ONE MONTH from the date of this Notification or within the time remaining in the response set forth in the Notification of Missing Requirements, whichever is the longer. No extension of this time limit may be granted under 37 CFR

GenoVoxx GmbH
Innovationscampus Lübeck
Maria Göppert-Strasse 1
23562 Lübeck

HRB: 5384
UST-IdNr.:
DE 222285450

July 3rd, 2007, Marburg

Geschäftsführer:
Dr. Dmitry Cherkasov

Verified Statement

I, Dmitry Cherkasov, Dr. med., resident in Moislinger Muehlenweg 21, 23560 Luebeck, Germany, hereby declare that I am conversant with the German and the English languages and that I am the translator of the document attached and certify that to the best of my knowledge and belief the following is a true and correct English translation of the specification contained in the U.S. Patent Application 10/578,313.



Dmitry Cherkasov

Telefon:
+49-(0) 451 290 33 60
+49-(0) 179 778 58 29

Fax:
+49-(0) 451 290 33 33

e-mail:
info@genovoxx.de

web:
www.genovoxx.info

Bankverbindung:
Deutsche Bank Lübeck
Kontonummer: 9012980
BLZ: 23070700